NASDAQ:PSTV 26 September 2025

PSTV Stock on November 25, 2025: FDA Meeting, Nasdaq Extension and Humana Deal Put Plus Therapeutics Back in Focus

As traders log in on Tuesday, November 25, 2025, Plus Therapeutics is back on the radar thanks to a cluster of late‑November catalysts: an FDA Type B meeting for lead radiotherapeutic REYOBIQ™, a fresh 180‑day Nasdaq bid‑price extension, and a national coverage agreement with Humana for its CNSide® cancer diagnostic.

25 November 2025

NASDAQ:PSTV·NYSE:HUM

PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

UnitedHealthcare coverage win. On Sept. 25, Plus Therapeutics announced that UnitedHealthcare Insurance Company granted national coverage for its CNSide® CSF Tumor Cell Enumeration LDT for metastatic CNS cancer, effective Sept. 15. The deal potentially opens access to more than 51 million members nationwide and positions CNSide as a covered testing service for specialists treating leptomeningeal metastases—a devastating complication of advanced cancers. GlobeNewswire

26 September 2025

Biotechnology·NASDAQ:PSTV·NASDAQ:UNH·Stock Market

NASDAQ:PSTV 26 September 2025 - 25 November 2025

PSTV Stock on November 25, 2025: FDA Meeting, Nasdaq Extension and Humana Deal Put Plus Therapeutics Back in Focus

PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients